Was the QuidelOrtho (QDEL) CFO’s share disposition an open‑market sale?

The filing explains the disposition of 1,806 common shares was to satisfy tax withholding obligations related to the restricted stock unit release. This indicates shares were withheld by the issuer for taxes rather than sold as a discretionary open‑market transaction.

QuidelOrtho CFO reports RSU vesting and tax withholding

QuidelOrtho Corp Chief Financial Officer Joseph M. Busky reported equity compensation activity involving restricted stock units and common shares.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

QuidelOrtho Corp Chief Financial Officer Joseph M. Busky reported equity compensation activity involving restricted stock units and common shares. On February 8, 2026, 5,968 restricted stock units were converted into 5,968 shares of common stock at a stated price of $0.

In connection with this release, 1,806 common shares at $29.1 per share were withheld by the issuer to satisfy tax withholding obligations, leaving Busky with 41,412 common shares held directly. He also reports 6,920 common shares held indirectly by a trust.

The filing notes that 5,968 shares vested on each of February 8, 2025 and February 8, 2026, and 5,969 additional shares are scheduled to vest on February 8, 2027, reflecting an ongoing multi‑year restricted stock unit vesting schedule.

Insider Trade Summary

5,968 shares exercised/converted

Exercise 4 txns

Insider Busky Joseph M.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	5,968	$0.00	$0.00
Grant/Award	Common Stock	5,968	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	1,806	$29.10	$53K
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Units — 5,969 contracts (Direct); Common Stock — 41,412 shares (Direct); Common Stock — 6,920 shares (Indirect, By Trust)

Footnotes (4)

F1. Reflects release of restricted stock units that were previously reported on a Form 4.
F2. Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units.
F3. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
F4. 5,968 shares vested on each of February 8, 2025 and February 8, 2026; and the remaining 5,969 shares will vest on February 8, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did QuidelOrtho (QDEL) CFO Joseph M. Busky report?

QuidelOrtho CFO Joseph M. Busky reported the release of 5,968 restricted stock units into common shares. The transaction reflects routine equity compensation, with shares delivered at a stated price of $0 and associated tax withholding handled through share disposition.

How many QuidelOrtho (QDEL) shares did the CFO receive and what was withheld for taxes?

Busky received 5,968 QuidelOrtho common shares upon restricted stock unit release. Of these, 1,806 shares at $29.1 per share were disposed of to satisfy tax withholding obligations, with the balance increasing his directly held common stock position reported in the filing.

How many QuidelOrtho (QDEL) shares does the CFO own after this Form 4 transaction?

After the reported transactions, Busky beneficially owns 41,412 QuidelOrtho common shares directly. He also reports indirect beneficial ownership of 6,920 additional common shares held by a trust, as disclosed separately in the holdings table of the filing.

What do the restricted stock units in the QuidelOrtho (QDEL) Form 4 represent?

Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. When units vest, they convert into common shares, as shown by the 5,968 restricted stock units that were released into an equal number of common shares in this filing.

What is the vesting schedule for the QuidelOrtho (QDEL) CFO’s restricted stock units?

The filing states that 5,968 shares vested on February 8, 2025 and another 5,968 on February 8, 2026. The remaining 5,969 shares from this award are scheduled to vest on February 8, 2027, indicating a three‑year vesting structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/10/2026 - 04:09 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Busky Joseph M.

(Last)

(First)

(Middle)

9975 SUMMERS RIDGE ROAD

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
QuidelOrtho Corp [ QDEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/08/2026		A		5,968⁽¹⁾	A	$0	43,218	D
Common Stock	02/08/2026		F		1,806⁽²⁾	D	$29.1	41,412	D
Common Stock								6,920	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽³⁾	02/08/2026		M			5,968	⁽⁴⁾	⁽⁴⁾	Common Stock	5,968	$0	5,969	D

Explanation of Responses:

1. Reflects release of restricted stock units that were previously reported on a Form 4.

2. Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units.

3. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.

4. 5,968 shares vested on each of February 8, 2025 and February 8, 2026; and the remaining 5,969 shares will vest on February 8, 2027.

Remarks:

	/s/ Phillip S. Askim, attorney-in-fact for Joseph M. Busky	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR